Clinical Report: Obinutuzumab in Refractory Minimal Change Disease
Overview
This case series highlights the use of obinutuzumab in two obese patients with refractory minimal change disease (MCD) who previously failed rituximab treatment. Both patients achieved complete remission following obinutuzumab administration, suggesting its potential as an effective alternative in this population.
Background
Minimal change disease (MCD) is a common cause of nephrotic syndrome in adults, often requiring immunosuppressive therapy. Obesity is a prevalent comorbidity that may adversely affect treatment responses due to associated chronic inflammation and B-cell dysfunction. Obinutuzumab, a type II anti-CD20 monoclonal antibody, offers a promising alternative for patients with inadequate responses to rituximab.
Data Highlights
Patient
BMI (kg/m²)
Initial Proteinuria (g/24 h)
Remission Duration (months)
1
32.10
8.00
26+
2
42.45
Not specified
Not specified
Key Findings
Obinutuzumab led to complete remission in two obese patients with refractory MCD.
Patient 1 maintained remission for over 26 months post-obinutuzumab treatment.
Patient 2 experienced a relapse after immunosuppressant cessation but regained remission with a subsequent obinutuzumab dose.
Both patients had previously inadequate responses to rituximab.
Obesity may influence treatment response and should be considered in managing MCD.
Clinical Implications
The findings suggest that obinutuzumab may be a viable treatment option for obese patients with refractory MCD who do not respond adequately to rituximab. Clinicians should consider the impact of obesity on treatment outcomes when managing MCD.
Conclusion
Obinutuzumab shows promise as an effective therapy for refractory MCD in obese patients, warranting further investigation into its role in this population.
